Literature DB >> 9780167

Critical involvement of Tcf-1 in expansion of thymocytes.

M W Schilham1, A Wilson, P Moerer, B J Benaissa-Trouw, A Cumano, H C Clevers.   

Abstract

T cell maturation in Tcf-1(-/-) mice deteriorates progressively and halts completely around 6 mo of age. During fetal development thymocyte subpopulations seem normal, although total cell numbers are lower. By 4 to 6 wk of age, obvious blockades in the differentiation of CD4- 8- thymocytes are observed at two distinct stages (CD44+ 25+ and CD44- 25-), both of which are normally characterized by extensive proliferation. This lack of thymocyte expansion and/or differentiation was also observed when Tcf-1(-/-) progenitor cells from the aorta-gonad-mesonephros region (embryonic day 11.5), fetal liver (embryonic day 12.5/14.5), and fetal bone marrow (embryonic day 18.5) were allowed to differentiate in normal thymic lobes (fetal thymic organ cultures) or were injected intrathymically into normal recipients. Despite these apparent defects in thymocyte differentiation and expansion, adult Tcf-1(-/-) mice are immunocompetent, as they generate virus neutralizing Abs at normal titers. Furthermore, their peripheral T cells have an activated phenotype (increased CD44 and decreased CD62L expression) and proliferate normally in response to Ag or mitogen, suggesting that these cells may have arisen from the early wave of development during embryogenesis and are either long lived or have subsequently been maintained by peripheral expansion. As Tcf-1 is a critical component in the Wnt/beta-catenin signaling pathway, these data suggest that Wnt-like factors play a role in the expansion of double-negative thymocytes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9780167

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  88 in total

1.  Homeostatic expansion and phenotypic conversion of naïve T cells in response to self peptide/MHC ligands.

Authors:  W C Kieper; S C Jameson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

2.  NKG2D receptor regulates human effector T-cell cytokine production.

Authors:  Amorette Barber; Charles L Sentman
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

Review 3.  Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy.

Authors:  Luca Gattinoni; Yun Ji; Nicholas P Restifo
Journal:  Clin Cancer Res       Date:  2010-08-05       Impact factor: 12.531

4.  Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1.

Authors:  Xinyuan Zhou; Shuyang Yu; Dong-Mei Zhao; John T Harty; Vladimir P Badovinac; Hai-Hui Xue
Journal:  Immunity       Date:  2010-08-27       Impact factor: 31.745

Review 5.  Forging T-Lymphocyte Identity: Intersecting Networks of Transcriptional Control.

Authors:  Ellen V Rothenberg; Jonas Ungerbäck; Ameya Champhekar
Journal:  Adv Immunol       Date:  2015-10-26       Impact factor: 3.543

6.  Clinical implications of β-catenin protein expression in breast cancer.

Authors:  Ziyi Wang; Hao Zhang; Jianxin Hou; Jianing Niu; Zhenhai Ma; Haidong Zhao; Caigang Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 7.  Programming CD8+ T cells for effective immunotherapy.

Authors:  Christian S Hinrichs; Luca Gattinoni; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2006-04-17       Impact factor: 7.486

8.  Wnt signaling induces matrix metalloproteinase expression and regulates T cell transmigration.

Authors:  Beibei Wu; Steve P Crampton; Christopher C W Hughes
Journal:  Immunity       Date:  2007-02       Impact factor: 31.745

9.  Dysregulation of Frizzled 6 is a critical component of B-cell leukemogenesis in a mouse model of chronic lymphocytic leukemia.

Authors:  Qing-Li Wu; Claudia Zierold; Erik A Ranheim
Journal:  Blood       Date:  2009-01-28       Impact factor: 22.113

Review 10.  TCF1 and beta-catenin regulate T cell development and function.

Authors:  Qing Yu; Archna Sharma; Jyoti Misra Sen
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.